Published in Eur J Cancer on August 01, 2003
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity | NCT02518191
Technological innovation and inequality in health. Demography (2008) 1.87
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2010) 1.48
Breast cancer in young women. Breast Cancer Res (2010) 1.31
Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J Cancer Res Clin Oncol (2006) 0.87
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. J Cancer Res Clin Oncol (2005) 0.86
Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast (2009) 0.85
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial. Oncol Rep (2013) 0.85
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br J Cancer (2005) 0.84
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer. BMC Cancer (2012) 0.81
The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy. Ecancermedicalscience (2013) 0.79
An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol (2009) 0.76
Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women. Geburtshilfe Frauenheilkd (2016) 0.75
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer. Cancer Res Treat (2016) 0.75
Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview. Wien Med Wochenschr (2010) 0.75
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
A Wilcoxon-type test for trend. Stat Med (1985) 13.22
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Doctor-patient communication: a review of the literature. Soc Sci Med (1995) 10.48
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol (1999) 8.60
Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst (1994) 7.91
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet (1993) 7.46
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Assessment and comparison of prognostic classification schemes for survival data. Stat Med (1999) 5.94
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer (1996) 5.24
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med (1992) 5.18
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet (2002) 5.04
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. Lancet (1986) 4.55
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med (1992) 3.70
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology (1986) 3.70
Double-blind placebo-controlled study of the hyperventilation provocation test and the validity of the hyperventilation syndrome. Lancet (1996) 3.42
Mild cervical dyskaryosis: safety of cytological surveillance. Lancet (1992) 3.09
Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol (2008) 3.07
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol (1999) 2.85
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Building multivariable regression models with continuous covariates in clinical epidemiology--with an emphasis on fractional polynomials. Methods Inf Med (2005) 2.54
Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol (2012) 2.45
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet (1995) 2.45
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep (1987) 2.37
Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg (1984) 2.36
Effect of smoking cessation on cervical lesion size. Lancet (1996) 2.35
[Joint decisions, how? Physician-patient communication about palliative chemotherapy]. Ned Tijdschr Geneeskd (1997) 2.34
Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature (1986) 2.32
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer (1996) 2.30
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet (1996) 2.23
Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1 : EAGLE Study report no. 1. Graefes Arch Clin Exp Ophthalmol (2005) 2.19
Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry (1996) 2.17
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol (1994) 2.11
Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J (1999) 2.09
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy. Br J Cancer (1996) 2.01
Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med (1996) 1.99
Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer (1991) 1.97
Therapy of small breast cancer: a prospective study on 1036 patients with special emphasis on prognostic factors. Int J Radiat Oncol Biol Phys (1992) 1.96
Accelerated decline in cervical cancer mortality in England and Wales. Lancet (1995) 1.95
Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol (1998) 1.94
Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry (1998) 1.94
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer (2004) 1.93
Psychosexual trauma of an abnormal cervical smear. Br J Obstet Gynaecol (1988) 1.90
Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ (1988) 1.89
Neuropsychologic correlates of MRI white matter hyperintensities: a study of 150 normal volunteers. Neurology (1993) 1.85
The Sexual Activity Questionnaire: a measure of women's sexual functioning. Qual Life Res (1996) 1.85
Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J Pathol (2001) 1.82
A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen (2004) 1.81
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial) Ann Oncol (2000) 1.80
Nosocomial and community-acquired infections in Germany. Summary of the results of the First National Prevalence Study (NIDEP) Infection (1997) 1.78
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 1.77
The quality of life of cancer patients: a review of the literature. Soc Sci Med (1985) 1.76
The use of cervicography in a primary screening service. Br J Obstet Gynaecol (1991) 1.76
Light chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma: Medical Research Council's Working Party for Leukaemia in Adults and the Oxford Lymphoma Group. Int J Cancer (1979) 1.75
Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis (2003) 1.75
Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol (1992) 1.74
A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J (2006) 1.73
Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovasc Dis (2002) 1.72
Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer (1996) 1.71
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut (1998) 1.68
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. J Clin Oncol (1991) 1.67
Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet (1988) 1.66
Extended preoperative polyvinyl alcohol microembolization of intracranial meningiomas: assessment of two embolization techniques. AJNR Am J Neuroradiol (1993) 1.63
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol (1993) 1.60
Resampling and cross-validation techniques: a tool to reduce bias caused by model building? Stat Med (1997) 1.60